Base title: prevent cancer preclinical drug development program: preclinical efficacy and endpoint biomarkers; task order title: efgr and kras vaccine to prevent lung cancer
Ended Awarded Last action
- Contract number
- 75N91020F00002
- Awardee
-
University Of Oklahoma UEI GY8NMUZQXVS7 Part of University Of Oklahoma
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $884,341
Award facts
- Opportunity
- Contract value 100% obligated
- $884,341.08 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
- Place of performance
- Oklahoma City, OK 73104, USA
- Legislative mandates
-
- Walsh-Healey Public Contracts Act FAR subpart 22.6
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Funding Only Action | -$6,532 | |
| Supplemental Agreement for work within scope | $0 | |
| Other Administrative Action | $0 | |
| Original award | $890,873 |
About this award
This federal contract was awarded by the National Cancer Institute (NCI), part of the Department of Health and Human Services (HHS), to the University of Oklahoma (OU) to support the PREVENT Preclinical Drug Development Program. The $884,341.08 firm-fixed-price contract task order is for the development of an EGFR and KRAS vaccine to prevent lung cancer.
Key subcontractors include The Methodist Hospital (doing business as Houston Methodist Hospital) and the Medical College of Wisconsin. The subcontractors will provide expertise and services related to chemoprevention using preclinical lung cancer models, optimal delivery of aerosolized miRNA to the lung, and developing immunochemoprevention for lung cancer. This contract does not have a set-aside designation.
Quick answers
Who was awarded contract 75N91020F00002?
75N91020F00002 was awarded to University Of Oklahoma by National Cancer Institute (National Institutes of Health) on June 1, 2020.
How much is contract 75N91020F00002 worth?
The government has obligated $884,341 on 75N91020F00002.
Is contract 75N91020F00002 an order under another contract?
Yes. 75N91020F00002 is a delivery order under 75N91019D00020, an indefinite delivery contract, on PREVENT Preclinical Drug Development Program (PREVENT).
Was contract 75N91020F00002 competed?
The extent of competition for 75N91020F00002 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award